New chemo drug may be more effective in certain patient groups
A phase three clinical trial of eribulin mesylate suggested it may be the optimal treatment in certain patient populations.
Results from a phase three clinical trial indicate that a potential new chemotherapy drug called eribulin mesylate could be more effective than the commonly-administered capecitabine in certain types of cancer patients.
As medical advancements are made, treatment of the disease is becoming increasingly personalised in order to ensure the most favourable outcomes, and the new medicine could help doctors better tailor their curative or palliative strategies.
Findings presented by Dr Peter A Kaufman during the 2013 ASCO Annual Meeting, which was held in Chicago, indicate that eribulin mesylate is superior to the alternative in patients with three or more organs involved with metastatic breast cancer.
Those who have not undergone chemotherapy, which involves the administration of cytotoxic drugs to eradicate populations of diseased cells, for six months also stand to benefit, as do patients who have received anthracycline and/or a taxane therapies in the metastatic setting.
Dr Kaufman, of the Dartmouth-Hitchcock Geisel School of Medicine and Norris Cotton Cancer Center, said: "These exploratory analyses suggest that other patient subgroups may benefit from eribulin and further studies are warranted."
Related News
-
News Women in Pharma: Hiring Across the Gender Divide
In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News Revolutionising cancer treatment with mRNA-based therapeutics
Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours. -
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability
The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ... -
News Choosing the Right CDMO Partner: A Comprehensive Guide
Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance